← Back to Clinical Trials
Recruiting NCT04985630

NCT04985630 The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04985630
Status Recruiting
Phase
Sponsor Amazentis SA
Condition Healthy Aging
Study Type INTERVENTIONAL
Enrollment 250 participants
Start Date 2021-08-30
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
MitopurePomegranate Juice

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 250 participants in total. It began in 2021-08-30 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Open labelled, virtual home based study to assess the test repeatability and the failure/rejection rate of the samples collected at home by participants.

Eligibility Criteria

Inclusion Criteria: 1. Males and females 18 to 80 years of age; 2. Is in general good health, as determined by the research team; 3. Willingness to consume the investigation product, complete questionnaires and to complete the study; 4. Have given voluntary, electronic, informed consent to be a participant in the study. Exclusion Criteria: 1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial; 2. Volunteers who plan to donate blood during the study or within 30 days of completing the study; 3. Subject has a known allergy to the test material's active or inactive ingredients; 4. Subjects with unstable medical conditions; 5. Participation in a clinical research trial within 30 days prior to randomization; 6. Allergy or sensitivity to study ingredients; 7. Individuals who are cognitively impaired and/or who are unable to give informed consent; 8. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject; 9. Has taken antibiotics within the previous 30 days.

Contact & Investigator

Central Contact

Julie Faitg, PhD

✉ jfaitg@amazentis.com

📞 +41215521272

Principal Investigator

Anurag Singh, MD, PhD

PRINCIPAL INVESTIGATOR

Amazentis SA

Frequently Asked Questions

Who can join the NCT04985630 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Healthy Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04985630 currently recruiting?

Yes, NCT04985630 is actively recruiting participants. Contact the research team at jfaitg@amazentis.com for enrollment information.

Where is the NCT04985630 trial being conducted?

This trial is being conducted at San Francisco, United States.

Who is sponsoring the NCT04985630 clinical trial?

NCT04985630 is sponsored by Amazentis SA. The principal investigator is Anurag Singh, MD, PhD at Amazentis SA. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology